ClinicalTrials.gg
CompletedNCT03083873Updated Oct 12, 2023Results posted

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

A Phase 2 interventional study of LN-145 and LN-145-S1 in Squamous Cell Carcinoma of the Head and Neck, sponsored by Iovance Biotherapeutics, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
358th of 993
64 · median 41
Started
2017
with 48 others
Phase 2
359 of 1,099
58 open now
Registered
466th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 358th largest by enrollment of the 993 interventional ones that give a count, is one of 49 that started in 2017, is one of 359 in phase 2, and was the 466th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Read the detailed description

LN-145/LN-145-S1 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The cell transfer therapy used in this study involves patients receiving a NMA lymphodepletion preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • LN-145
  • Cell Therapy
  • Autologous Adoptive Cell Transfer
  • Autologous Adoptive Cell Therapy
  • Cellular Immuno-therapy
  • Tumor Infiltrating Lymphocytes
  • TIL
  • IL-2
  • LN-145-S1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be greater than 18 years of age at the time of consent.
  • Must have recurrent and/or , squamous cell carcinoma of the head and neck (both HPV-positive and -negative)
  • Must have at least 1 lesion that is resectable for TIL generation.
  • Must have as defined by v1.1 following the surgical resection.
  • Must have received at least 1 and no more than 3 lines of prior systemic immunotherapy and/or chemotherapeutic treatments for HNSCC.
  • Any prior therapy directed at the malignant tumor must be discontinued at least 28 days prior to lymphodepletion.
  • Have an (ECOG) performance status of 0 or 1.
  • Patients must be seronegative for the .
  • Patients seropositive for virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or virus (anti-HCV) indicating acute or chronic infection may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment
  • Patients of and patients whose sexual partners are of childbearing potential must be willing to practice an approved method of highly effective starting at the time of and for 1 year after the completion of the study treatment regimen.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received an organ allograft or prior cell transfer therapy within the past 20 years.
  • Patients who are on a systemic therapy (greater than 10 mg of prednisone or equivalent). Patients receiving steroids as replacement therapy for adrenocortical insufficiency at \< 10 mg of prednisone or other steroid equivalent daily may be eligible.
  • Prior therapy-related toxicities Grade ≥ 1 according to Common Toxicity Criteria for Adverse Events () v4.03
  • Patients with documented Grade ≥ 2 diarrhea or colitis as a result of previous immunotherapy within six months from screening.
  • Patients who have a to or history of reaction to cyclophosphamide, mesna, fludarabine, IL-2, antibiotics of the aminoglycoside group (ie, gentamicin or streptomycin; excluding those who are skin-test negative for gentamicin hypersensitivity), any component of the TIL infusion product formulation including dimethylsulfoxide (DMSO), human serum albumin (HSA), IL-2, and dextran-40.
  • Patients with active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system.
  • Patients with symptomatic and/or untreated .
  • Have any form of primary or acquired immunodeficiency syndrome, such as severe combined immunodeficiency disease or acquired immune deficiency syndrome (AIDS).
  • Patients who have a (LVEF) \< 45% or who are (NYHA) Class 2 or higher.
  • Patients who have had another primary within the previous 3 years.
  • Patients who are pregnant, parturient, or breastfeeding women.
  • Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD regimen.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL

    Biological: LN-145

  • Experimental
    Cohort 2

    Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL

    Biological: LN-145

  • Experimental
    Cohort 3

    Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL

    Biological: LN-145

  • Experimental
    Cohort 4

    Treatment with LN-145-S1 cryopreserved TIL

    Biological: LN-145-S1

  • Experimental
    Cohort 5

    LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment

    Biological: LN-145 · Biological: LN-145-S1

Interventions

  • BiologicalLN-145

    Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

    Also known as: TIL, autologous tumor infiltrating lymphocytes

  • BiologicalLN-145-S1

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.

    Also known as: TIL, autologous tumor infiltrating lymphocytes

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    The percentage of patients who have a confirmed complete response or partial response as assessed by the investigator per RECIST v1.1. Objective response rate (ORR) will be defined as the percentage of the patients with a confirmed complete or partial response (CR or PR),by MRI or CT scan as per RECIST 1.1 criteria. Complete response (CR), Disappearance of all target and non-target lesions. All lymph nodes must be non-pathological in size(\<10mm short axis). No new lesions. Partial response (PR), At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Persistence of one or more non-target lesion(s) and/or maintenance above the normal limits (Non-CR/Non-PD). No new lesions.

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response

    To evaluate efficacy parameters such as Duration of Response (DOR) using RECIST v1.1 as assessed by the Investigator. DOR is measured from the time point at which the initial measurement criteria per RECIST v1.1 are met for a CR or PR (if response is a confirmed response), whichever response is observed first, until PD.

    Time frame: Up to 24 months

  2. Disease Control Rate

    The percentage of patients who have a best overall response of complete response, partial response, or stable disease as assessed by the investigator per RECIST v1.1. The BOR of SD must be at least 4 weeks from LN-145/LN-145-S1 infusion.

    Time frame: Up to 24 months

  3. Progression-Free Survival

    The time (in months) from the date of the TIL infusion to progressive disease as assessed by the Investigator using RECIST v1.1 or death due to any cause, whichever occurs earlier. Progression was defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of diameters of the target lesions and an absolute increase of at least 5 mm, and/or unequivocal progression of existing non-target lesions, and/or the appearance of 1 or more new lesions.

    Time frame: Up to 24 months

07

Results

Posted Oct 12, 2023

Participant flow

This study was conducted at 20 centers that screened participants and 18 that enrolled participants in the United States, Jan 2017 through Aug 2022.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started102219130
Infused with til81716120
Completed assessment period8151190
Completed00000
Not completed102219130
Withdrew: Death6151390
Withdrew: Sponsor terminated study01230
Withdrew: Lost to follow-up01100
Withdrew: Withdrawal by subject20000
Withdrew: Did not receive til25310

Outcome measures

PrimaryObjective Response Rate

The percentage of patients who have a confirmed complete response or partial response as assessed by the investigator per RECIST v1.1. Objective response rate (ORR) will be defined as the percentage of the patients with a confirmed complete or partial response (CR or PR),by MRI or CT scan as per RECIST 1.1 criteria. Complete response (CR), Disappearance of all target and non-target lesions. All lymph nodes must be non-pathological in size(\<10mm short axis). No new lesions. Partial response (PR), At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Persistence of one or more non-target lesion(s) and/or maintenance above the normal limits (Non-CR/Non-PD). No new lesions.

Time frame:
Up to 24 months
Reported as:
Number · percentage of patients
Objective Response Rate
percentage of patientsCohort 1Cohort 2Cohort 3Cohort 4
Objective Response Rate37.5 (8.5 to 75.5)5.9 (0.1 to 28.7)0 (0 to 20.6)16.7 (2.1 to 48.4)
SecondaryDuration of Response

To evaluate efficacy parameters such as Duration of Response (DOR) using RECIST v1.1 as assessed by the Investigator. DOR is measured from the time point at which the initial measurement criteria per RECIST v1.1 are met for a CR or PR (if response is a confirmed response), whichever response is observed first, until PD.

Time frame:
Up to 24 months
Reported as:
Median · Months
Duration of Response
MonthsCohort 1Cohort 2Cohort 3Cohort 4
Duration of Response3.1 (2.8 to 7.6)NA (NA to NA)—NA (7.6 to NA)
SecondaryDisease Control Rate

The percentage of patients who have a best overall response of complete response, partial response, or stable disease as assessed by the investigator per RECIST v1.1. The BOR of SD must be at least 4 weeks from LN-145/LN-145-S1 infusion.

Time frame:
Up to 24 months
Reported as:
Number · percentage of patients
Disease Control Rate
percentage of patientsCohort 1Cohort 2Cohort 3Cohort 4
Disease Control Rate87.5 (47.3 to 99.7)70.6 (44.0 to 89.7)75.0 (47.6 to 92.7)75.0 (42.8 to 94.5)
SecondaryProgression-Free Survival

The time (in months) from the date of the TIL infusion to progressive disease as assessed by the Investigator using RECIST v1.1 or death due to any cause, whichever occurs earlier. Progression was defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of diameters of the target lesions and an absolute increase of at least 5 mm, and/or unequivocal progression of existing non-target lesions, and/or the appearance of 1 or more new lesions.

Time frame:
Up to 24 months
Reported as:
Median · Months
Progression-Free Survival
MonthsCohort 1Cohort 2Cohort 3Cohort 4
Progression-Free Survival2.8 (0.9 to 3.9)1.9 (1.6 to 2.8)2.8 (1.8 to 3.1)1.9 (0.6 to 9.0)

Adverse events

Collected over 5 years, 5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 16/8 (75%)5/8 (62.5%)8/8 (100%)
Cohort 215/17 (88.2%)9/17 (52.9%)17/17 (100%)
Cohort 313/16 (81.3%)11/16 (68.8%)16/16 (100%)
Cohort 49/12 (75%)8/12 (66.7%)12/12 (100%)
Cohort 5———
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Febrile neutropeniaBlood and lymphatic system disorders2/84/172/162/12—
PneumoniaInfections and infestations2/80/171/160/12—
Respiratory failureRespiratory, thoracic and mediastinal disorders0/80/172/163/12—
HypotensionVascular disorders0/80/173/162/12—
Myocardial infarctionCardiac disorders1/80/170/160/12—
Sinus tachycardiaCardiac disorders1/80/170/160/12—
Device related infectionInfections and infestations1/80/170/160/12—
DehydrationMetabolism and nutrition disorders1/80/170/160/12—
SomnolenceNervous system disorders1/80/170/160/12—
AspirationRespiratory, thoracic and mediastinal disorders1/80/170/160/12—
Most frequent other events
Showing 10 of 205
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Thrombocytopenia [4]Blood and lymphatic system disorders4/812/1712/1610/12—
ChillsGeneral disorders6/812/177/167/12—
AnaemiaBlood and lymphatic system disorders4/87/179/168/12—
PyrexiaGeneral disorders5/810/177/164/12—
HyponatraemiaMetabolism and nutrition disorders5/85/173/163/12—
HypotensionVascular disorders5/86/177/167/12—
HypophosphataemiaMetabolism and nutrition disorders4/86/179/163/12—
Lymphopenia [2]Blood and lymphatic system disorders4/85/172/162/12—
Neutropenia [3]Blood and lymphatic system disorders3/85/175/166/12—
HypocalcaemiaMetabolism and nutrition disorders2/85/178/163/12—

Baseline characteristics

The Safety Analysis Set is defined as patients who have received LN-145/LN-145-S1 infusion.

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
<=18 years000000
Between 18 and 65 years8101210040
>=65 years0742013
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Median57 (24 to 64)58 (37 to 71)56 (34 to 67)56.5 (50 to 75)—57 (24 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Female1222—7
Male7151410—46
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Hispanic or Latino0012—3
Not Hispanic or Latino7171410—48
Unknown or Not Reported1010—2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
American Indian or Alaska Native0000—0
Asian0002—2
Native Hawaiian or Other Pacific Islander0000—0
Black or African American0111—3
White816159—48
More than one race0000—0
Unknown or Not Reported0000—0
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
United States8171612—53
08

Study locations

22 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • University of California, Los Angeles
    Los Angeles, California 90024, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Christiana Care Health System
    Newark, Delaware 19718, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kansas
    Westwood, Kansas 66205, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Louisiana State University - Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Providence Cancer Center Oncology and Hematology Care Clinic
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Aug 2022, 66 months.

Results were first posted in Oct 2023, 1 year 2 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 66 months is above that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Mar 20, 2017
StartActual
Jan 9, 2017
Primary completionActual
Aug 8, 2022
CompletionActual
Aug 8, 2022
Results first posted
Oct 12, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03083873
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Jan 9, 2017
Primary completion
Aug 8, 2022
Completion
Aug 8, 2022
Results posted
Oct 12, 2023
Last update
Oct 12, 2023

Study contacts

Iovance Biotherapeutics Medical Monitor
study director · Iovance Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

Start the discussion